Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
Pancreatic cancer remains one of the most lethal and poorly understood human malignancies and will continue to be a major unsolved health problem in the 21st century. Despite efforts over the past three decades to improve diagnosis and treatment, the prognosis for patients with pancreatic cancer is...
Main Authors: | Tamburrino, Anna, Piro, Geny, Carbone, Carmine, Tortora, Giampaolo, Melisi, Davide |
---|---|
Format: | Online |
Language: | English |
Published: |
Frontiers Media S.A.
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639407/ |
Similar Items
-
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
by: Carbone, Carmine, et al.
Published: (2014) -
Reactive resistance to anti-angiogenic drugs
by: Bousquet, Guilhem, et al.
Published: (2015) -
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus
by: Brannon, A. Rose, et al.
Published: (2016) -
Tissue transglutaminase: a new target to reverse cancer drug resistance
by: Budillon, Alfredo, et al.
Published: (2011) -
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
by: Peters, Christina, et al.
Published: (2015)